T cell exclusion, immune privilege, and the tumor microenvironment
- PMID: 25838376
- DOI: 10.1126/science.aaa6204
T cell exclusion, immune privilege, and the tumor microenvironment
Abstract
Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This requires not only that cancer-specific T cells be generated, but also that these T cells physically contact cancer cells. The coexistence in some patients of cancer cells and T cells that recognize them indicates that tumors may exhibit the phenomenon of immune privilege, in which immunogenic tissue is protected from immune attack. Here, we review the evidence that stromal cells of the tumor microenvironment mediate this restriction by excluding T cells from the vicinity of cancer cells. Overcoming this T cell checkpoint may thus enable optimal immunotherapy.
Copyright © 2015, American Association for the Advancement of Science.
Similar articles
-
Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68. Nihon Rinsho Meneki Gakkai Kaishi. 2017. PMID: 28539557 Review.
-
Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment.Scand J Immunol. 2013 Jul;78(1):50-60. doi: 10.1111/sji.12065. Scand J Immunol. 2013. PMID: 23659474
-
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.Cancer Res. 2001 Mar 1;61(5):1948-56. Cancer Res. 2001. PMID: 11280751
-
Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.Clin Cancer Res. 2005 Aug 1;11(15):5566-71. doi: 10.1158/1078-0432.CCR-05-0699. Clin Cancer Res. 2005. PMID: 16061874
-
Improving homing in T cell therapy.Cytokine Growth Factor Rev. 2017 Aug;36:107-116. doi: 10.1016/j.cytogfr.2017.06.009. Epub 2017 Jun 23. Cytokine Growth Factor Rev. 2017. PMID: 28690108 Review.
Cited by
-
Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1.Cancer Cell Int. 2024 Nov 20;24(1):385. doi: 10.1186/s12935-024-03557-1. Cancer Cell Int. 2024. PMID: 39568023 Free PMC article.
-
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model.Front Immunol. 2024 Nov 4;15:1387229. doi: 10.3389/fimmu.2024.1387229. eCollection 2024. Front Immunol. 2024. PMID: 39559365 Free PMC article.
-
Histology Agnostic Drug Development: An Updated Review.Cancers (Basel). 2024 Oct 29;16(21):3642. doi: 10.3390/cancers16213642. Cancers (Basel). 2024. PMID: 39518080 Free PMC article. Review.
-
Understanding the interplay between extracellular matrix topology and tumor-immune interactions: Challenges and opportunities.Oncotarget. 2024 Nov 7;15:768-781. doi: 10.18632/oncotarget.28666. Oncotarget. 2024. PMID: 39513932 Free PMC article. Review.
-
DDR1 is identified as an immunotherapy target for microsatellite stable colon cancer by CRISPR screening.NPJ Precis Oncol. 2024 Nov 7;8(1):253. doi: 10.1038/s41698-024-00743-2. NPJ Precis Oncol. 2024. PMID: 39511298 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
